Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Associate

Brittany C. Morreale

Goodwin Procter

main

Morreale Brittany

Goodwin Associate Brittany Morreale, from Boston, practices in the firm’s Business Law Department. Learn more about Brittany's experience and recent cases.

Brittany C. Morreale

Areas of Practice

Professional Activities

Credentials

Education

JD2017

BA2013

Admissions

Bars

Recognition & Awards

Related Content

Goodwin Advises Anika on Strategic Update of Business with Sale of Arthrosurface

Goodwin Advises eGenesis on $191 million Series D Funding Round

Goodwin Advises Flagship Pioneering on Partnership with GSK with Initial Funding Up to $150M

Entrada Therapeutics Closes $100 Million Registered Direct Offering

Flagship Pioneering and Novo Nordisk Partner on Research Collaboration with Metaphore Biotechnologies, Inc.

Novo Nordisk Enters into Research Collaborations with Omega Therapeutics and Cellarity on Novel Treatment Approaches for Cardiometabolic Diseases

Flagship Pioneering and Pfizer Partner to Accelerate Development of Innovative Medicines Targeting Unmet Needs with $100 Million Combined Commitment

Entrada Therapeutics to Collaborate With Vertex Pharmaceuticals on EEV-Therapeutics, for $250 Million in Equity and Upfront Payments, Up to $485 Million in Milestone Payments, and Royalties

Late Stage Drug Development

Mergers & Acquisitions